U.S. Skin Grafts Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2032

U.S. Skin Grafts Market Size

• The U.S. skin grafts market size was valued at USD 484.70 million in 2024 and is expected to reach USD 883.95 million by 2032, at a CAGR of 7.80% during the forecast period
• The market growth is largely fueled by the increasing prevalence of chronic wounds, burns, and trauma-related injuries, coupled with advancements in regenerative medicine and tissue engineering technologies
• Furthermore, rising demand for advanced, biocompatible, and patient-specific graft solutions in hospitals and specialized care centers is establishing skin grafts as a critical component in wound management and reconstructive procedures. These converging factors are accelerating the adoption of innovative skin graft solutions, thereby significantly boosting the industry's growth

U.S. Skin Grafts Market Analysis

• Skin grafts, providing replacement or repair of damaged skin tissue, are increasingly vital components of advanced wound care and reconstructive procedures in hospitals and specialized care centers due to their effectiveness in promoting healing, reducing infection risks, and improving cosmetic outcomes
• The escalating demand for skin grafts is primarily fueled by the rising prevalence of chronic wounds, burns, and trauma-related injuries, coupled with advancements in tissue engineering, bioengineered grafts, and regenerative medicine technologies
• The U.S. skin grafts market is driven by high healthcare expenditure, advanced medical infrastructure, and increasing adoption of innovative graft solutions, with hospitals and burn centers investing in next-generation autologous and allogeneic grafts for faster recovery and better patient outcomes
• Growing awareness among patients and healthcare providers regarding the benefits of bioengineered and synthetic skin substitutes is boosting adoption, particularly in reconstructive surgeries and chronic wound management
• Extensive wound applications dominated the U.S. skin grafts market with a market share of 38.7% in 2024, driven by the growing incidence of traumatic injuries and chronic ulcers requiring advanced grafting solutions for effective healing

Report Scope and U.S. Skin Grafts Market Segmentation        

U.S. Skin Grafts Market Trends

“Advancements in Bioengineered and Synthetic Grafts”

• A significant and accelerating trend in the U.S. skin grafts market is the increasing adoption of bioengineered and synthetic skin substitutes, enhancing healing outcomes and reducing dependency on donor sites
• For instance, Integra LifeSciences’ dermal regeneration templates allow rapid wound closure while minimizing scarring and donor site morbidity in burn and chronic wound patient
• Innovations in 3D bioprinting and tissue engineering enable customized grafts tailored to patient-specific wound geometry, improving graft take and functional recovery
• The integration of growth factors, antimicrobial coatings, and scaffolding materials in skin substitutes is facilitating faster tissue regeneration and reduced infection risk
• This trend towards advanced, patient-specific, and multifunctional graft solutions is reshaping clinical practices, with companies such as Organogenesis developing next-generation grafts incorporating regenerative and antimicrobial properties
• The demand for bioengineered and synthetic skin grafts is growing rapidly across hospitals and specialized care centers, as clinicians increasingly prioritize faster healing, reduced complications, and improved aesthetic outcomes

U.S. Skin Grafts Market Dynamics

Driver

“Rising Incidence of Burns, Chronic Wounds, and Trauma”

• The increasing prevalence of severe burns, chronic ulcers, and trauma-related injuries is a significant driver for the heightened demand for skin graft procedures in the U.S.
• For instance, the growing number of burn victims and diabetic ulcer patients has intensified hospital investments in advanced graft solutions for improved recovery outcomes
• Skin grafts offer reliable tissue coverage, promote faster healing, and reduce infection risks, providing a compelling clinical advantage over traditional wound care methods
• The rising awareness among healthcare providers regarding regenerative medicine and advanced wound management techniques is further driving graft adoption
• Hospitals and specialized care centers are increasingly integrating autologous, allogeneic, and synthetic grafts into their wound care protocols to optimize treatment outcomes
• The convenience of ready-to-use graft solutions, compatibility with advanced surgical instruments, and improved patient recovery timelines are key factors propelling the adoption of skin grafts in U.S. healthcare facilities

Restraint/Challenge

“High Cost and Regulatory Compliance Hurdles”

• Concerns regarding the high cost of advanced skin grafts and the complex regulatory landscape pose significant challenges to broader market adoption in the U.S.
• For instance, premium bioengineered grafts or 3D bioprinted solutions often come with elevated price points, limiting accessibility for smaller hospitals or outpatient clinics
• Navigating FDA approvals, clinical trial requirements, and reimbursement policies can delay product launches and slow market penetration
• Healthcare providers may hesitate to adopt new graft technologies without clear guidelines on efficacy, safety, and cost-effectiveness
• While prices of some conventional grafts remain stable, advanced graft solutions with regenerative features, antimicrobial coatings, or custom bioprinting capabilities carry a premium that can deter adoption
• Overcoming these challenges through streamlined regulatory processes, cost reduction strategies, and improved insurance reimbursement coverage will be vital for sustained market growth

U.S. Skin Grafts Market Scope

The market is segmented on the basis of graft type, graft thickness, applications, equipment, and end users.

• By Graft Type

On the basis of graft type, the U.S. skin grafts market is segmented into autologous, isogeneic, allogeneic, xenogeneic, and prosthetic. The autologous segment dominated the market with the largest revenue share of 46.3% in 2024, driven by its high success rate and minimal risk of immune rejection. Autografts use the patient’s own skin, making them highly compatible and effective for burns, chronic wounds, and reconstructive procedures. They offer faster healing, lower complication rates, and reduced infection risk compared to other graft types. Extensive clinical experience and well-established surgical protocols further strengthen adoption. Hospitals and burn centers prefer autografts for their reliability and proven outcomes. Advanced harvesting tools such as motorized dermatomes also enhance the precision and success of autograft procedures.

The allogeneic segment is anticipated to witness the fastest growth rate from 2025 to 2032, fueled by the increasing availability of donor skin banks and the urgent need for immediate wound coverage. Allogeneic grafts provide temporary or permanent coverage when autografts are not feasible. Innovations in tissue preservation, sterilization, and bioengineering have improved graft survival and reduced rejection risks. Rising awareness among healthcare providers and patients regarding donor-derived graft benefits is driving adoption. Hospitals increasingly use allogeneic grafts in severe burn and trauma care. The segment is supported by ongoing research in immune-modulated and bioengineered grafts for better outcomes.

• By Graft Thickness

On the basis of graft thickness, the U.S. skin grafts market is segmented into split-thickness, full-thickness, and composite grafts. The split-thickness segment dominated in 2024 due to its versatility in covering large wounds effectively. Split-thickness grafts are widely used for burns, chronic ulcers, and extensive skin loss, providing quicker healing and higher take rates than full-thickness grafts. They cause minimal donor site morbidity and are easier to harvest. Technological advancements in dermatomes allow precise and uniform graft thickness. Their compatibility with advanced wound care products enhances clinical outcomes. Hospitals and wound care centers favor split-thickness grafts for high-volume procedures.

The composite graft segment is expected to witness the fastest growth from 2025 to 2032, driven by its use in reconstructive and cosmetic procedures requiring both skin and underlying tissue layers. These grafts are preferred in facial, nasal, and hand reconstructions for functional and aesthetic restoration. Microsurgical techniques and tissue engineering improve graft survival rates and long-term results. Rising demand for cosmetically favorable outcomes is boosting adoption. Research in scaffold-based composite grafts is expanding possibilities in complex reconstructions. Hospitals and specialty centers are increasingly adopting these grafts for high-value surgeries.

• By Applications

On the basis of applications, the U.S. skin grafts market is segmented into extensive wound, burns, extensive skin loss due to infection, skin cancers, and others. The extensive wound segment dominated with a 38.7% market share in 2024, driven by the prevalence of trauma, pressure ulcers, and diabetic foot wounds. Hospitals and wound care centers rely heavily on skin grafts to cover these wounds, reduce infection, and accelerate healing. Growing patient awareness of advanced wound care therapies supports adoption. Clinical guidelines favor skin grafts for large or non-healing wounds. Advanced graft solutions such as bioengineered and synthetic grafts are increasingly used. The segment benefits from high procedural volumes in specialized care facilities.

The burns segment is anticipated to witness the fastest growth from 2025 to 2032, fueled by rising incidences of thermal and chemical burn injuries. Immediate wound coverage is critical to prevent infection and fluid loss in burn patients. Bioengineered and temporary skin substitutes complement traditional grafts for improved survival and cosmetic outcomes. Specialized burn care units and hospitals are expanding infrastructure to manage rising cases. Awareness campaigns and training in advanced burn management techniques increase adoption. Technological innovations in anti-infection and regenerative grafts further drive growth.

• By Equipment

On the basis of equipment, the U.S. skin grafts market is segmented into dermatome, general surgical instruments, consumables, and others. The dermatome segment dominated in 2024 due to its essential role in harvesting precise grafts with minimal donor site damage. Dermatome tools provide uniform thickness, improving graft take and clinical outcomes. Both manual and motorized dermatomes are widely used in hospitals and burn centers. Continuous technological improvements enhance safety, accuracy, and efficiency. Surgeons prefer dermatomes for split-thickness and full-thickness graft procedures. The segment benefits from high adoption in high-volume surgical centers.

The consumables segment is expected to witness the fastest growth from 2025 to 2032, driven by increasing demand for advanced dressings, scaffolds, and graft fixation materials. Consumables support infection control, faster healing, and improved graft integration. Growth is fueled by rising wound care procedures in hospitals and outpatient centers. Innovations in bioactive and antimicrobial consumables are enhancing graft outcomes. Hospitals are increasingly stocking specialized consumables to improve procedural efficiency. Expansion of wound care clinics further drives the segment’s adoption.

• By End Users

On the basis of end users, the U.S. skin grafts market is segmented into hospitals and clinics, academic and research institutes, and others. The hospitals and clinics segment dominated in 2024 due to the high concentration of surgical procedures, burn units, and wound care services in these facilities. Hospitals are the primary consumers of skin grafts for acute and chronic wounds. Specialized teams trained in advanced grafting techniques ensure better outcomes. Hospitals benefit from procurement systems, insurance reimbursements, and access to advanced surgical instruments. Clinical guidelines and high patient volumes support the segment. This segment also drives adoption of both conventional and advanced graft technologies.

The academic and research institutes segment is expected to witness the fastest growth from 2025 to 2032, fueled by ongoing research in regenerative medicine, tissue engineering, and 3D bioprinting of skin substitutes. These institutions focus on developing innovative graft solutions and evaluating clinical efficacy. Rising investments in experimental graft development and clinical trials are driving adoption. Research findings often translate into commercial and hospital applications. Collaboration with biotech companies accelerates the introduction of next-generation grafts. The segment contributes significantly to technological advancements in skin grafting.

U.S. Skin Grafts Market Share

The U.S. Skin Grafts industry is primarily led by well-established companies, including:

• Zimmer Biomet (U.S.)
• AlloSource (U.S.)
• Promethean (U.S.)
• AVITA Medical, Inc. (U.S.)
• Integra LifeSciences Corporation (U.S.)
• KERECIS (Iceland)
• Smith + Nephew (U.S.)
• ConvaTec Inc. (U.S.)
• Derma Sciences, Inc. (U.S.)
• Acelity L.P., Inc. (U.S.)
• Medtronic (Ireland)
• Baxter (U.S.)
• Johnson & Johnson and its affiliates (U.S.)
• 3M (U.S.)
• Mölnlycke AB (U.S.)
• Medline Industries, Inc. (U.S.)
• Cleveland Clinic (U.S.)
• American Board of Plastic Surgery, Inc. (U.S.)

What are the Recent Developments in U.S. Skin Grafts Market?

• In August 2025, Waterbury Hospital in Connecticut began using an innovative spray-on skin procedure called autologous cell therapy to treat deep and chronic wounds. This method utilizes a patient's own skin cells, processed into a sprayable suspension, to promote healing without traditional skin graft methods. The approach has shown promising results, such as reducing wound size by 50% in some patients, without the need for operating room procedures
• In June 2025, a Phase 3 clinical trial led by Stanford Medicine demonstrated that gene therapy skin grafts significantly improved healing, reduced pain, and lessened itching in patients with Epidermolysis Bullosa (EB). The genetically engineered grafts were granted approval as an EB therapy
• In April 2025, the U.S. Food and Drug Administration (FDA) approved genetically engineered skin grafts as a therapy for Epidermolysis Bullosa (EB), a rare and severe skin disorder. This approval followed a Phase 3 clinical trial demonstrating significantly better healing, reduced pain, and less itching in EB patients treated with the grafts compared to untreated wounds
• In February 2025, the Centers for Medicare & Medicaid Services (CMS) finalized Local Coverage Determinations (LCDs) for skin substitute grafts and Cellular and Tissue-Based Products (CTPs). These policies, govern the use of skin substitute grafts for Medicare Part B beneficiaries, covering chronic, non-infected diabetic foot ulcers and venous leg ulcers that fail to respond after four weeks of standard care treatment
• In January 2025, the Centers for Medicare & Medicaid Services (CMS) announced a delay in the effective date of their new skin substitute local coverage determinations (LCDs) until April 13, 2025. This delay was implemented to allow for further review and to ensure patient access to skin substitute products with high-quality evidence of effectiveness

SKU-18435